UCB reported EUR1.47B in Selling and Administration Expenses for its fiscal semester ending in December of 2025.





Selling And Administration Expenses Change Date
Alcon AG USD 964M 82M Jun/2026
Amarin USD 18.97M 1.03M Dec/2025
argenx SE USD 417M 62M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Bayer EUR 3.96B 267M Jun/2026
Genmab DKK 205M 39M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
GRIFOLS EUR 289M 8M Jun/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Lakefront Biotherapeutics EUR 22.5M 13M Jun/2026
Merck EUR 1.57B 49M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Orion EUR 98.9M 7M Jun/2026
Recordati EUR 201.58M 8.82M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
UCB EUR 1.47B 193M Dec/2025
Unibail Rodamco EUR 94.8M 4.8M Dec/2025